The AFCRPLITY score for predicting the prognosis of immunotherapy combined with local-regional therapy in unresectable hepatocellular carcinoma.

ABSTRACT:

Background

Immunotherapy combined with intra-arterial therapy (IAT) has shown great potential in the treatment of unresectable hepatocellular carcinoma (uHCC). However, there are currently no available biomarkers that can predict the prognosis of immune-based combined therapy.

Objectives

To establish a scoring method to predict prognosis in uHCC patients undergoing IAT plus immunotherapy.

Methods

Between March 2019 and August 2022, uHCC patients undergoing IAT in combination with programmed cell death (ligand) 1 (PD-1)/PD-L1-based immunotherapy were retrospectively analyzed.

Results

Among 1046 patients included, 780 patients were enrolled into hepatic arterial infusion chemotherapy immunotherapy cohorts (training set: n = 546, one center; external testin

SUBMITTER: Zuo M 

PROVIDER: S-EPMC11574904 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature